Ignacio Alvarez

Mr. Ignacio Alvarez

Neurology, University Hospital Mútua de Terrassa, Terrassa, Spain
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BKBrian W. Kunkle
Brian W. Kunkle
T(The European Alzheimer’s Disease Initiative (Eadi)
The European Alzheimer’s Disease Initiative (Eadi)
BGBenjamin Grenier-Boley
Benjamin Grenier-Boley
RSRebecca Sims
Rebecca Sims
JBJoshua C. Bis
Joshua C. Bis
MPMargaret A. Pericak-Vance
Margaret A. Pericak-Vance

4 April 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CBCéline Bellenguez
Céline Bellenguez
FKFahri Küçükali
Fahri Küçükali
IJIris E. Jansen
Iris E. Jansen
LKLuca Kleineidam
Luca Kleineidam
SMSonia Moreno-Grau
Sonia Moreno-Grau
JLJean-Charles Lambert
Jean-Charles Lambert
Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/‘proxy’ AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele.

1 December 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
MNMike A Nalls
Mike A Nalls
CBCornelis Blauwendraat
Cornelis Blauwendraat
KHKarl Heilbron
Karl Heilbron
SBSara Bandres-Ciga
Sara Bandres-Ciga
DCDiana Chang
Diana Chang
FZFutao Zhang
Futao Zhang

7 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
IRItziar de Rojas
Itziar de Rojas
SMSonia Moreno-Grau
Sonia Moreno-Grau
NTNiccolo Tesi
Niccolo Tesi
BGBenjamin Grenier-Boley
Benjamin Grenier-Boley
VAVictor Andrade
Victor Andrade
ARAgustín Ruiz
Agustín Ruiz
Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer’s disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer’s disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer’s disease.

11 November 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DWDaniel Western
Daniel Western
JTJigyasha Timsina
Jigyasha Timsina
LWLihua Wang
Lihua Wang
CWCiyang Wang
Ciyang Wang
CYChengran Yang
Chengran Yang
CCCarlos Cruchaga
Carlos Cruchaga

26 November 2020 in Neuron
Verified
Journal Article
Closed access
RDRamita Dewan
Ramita Dewan
RCRuth Chia
Ruth Chia
JDJinhui Ding
Jinhui Ding
RHRichard A. Hickman
Richard A. Hickman
TSThor D. Stein
Thor D. Stein
BTBryan J. Traynor
Bryan J. Traynor